Celera Narrowing Down Proteins in Prognostic Panel for Non-Small Cell Lung Cancer Detection

Celera is currently evaluating the clinical utility of two biomarker panels — one with nine proteins and one with six — in order to determine which assay to commercialize.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.